Skip to main content

Sequenom Announces Sale of Three MassArray Systems

NEW YORK, April 4 – Sequenom said Wednesday it has sold three MassArray Systems, bringing the company’s installed base to 29 sites worldwide.

Sequenom of San Diego said the announcement includes the sale of a second system to the Whitehead Institute’s Center for Genome Research and initial sales to Galileo Genomics, a population genetics company based in Montreal, and to an undisclosed customer.

Sequenom did not say how much the systems sold for, but in the past the company has said that the price of the MassArray is between $400,000 and $1.1 million depending on consumables. 

The news follows on the heals of an announcement last week in which Sequenom of San Diego said it completed the sale of four systems, including sales to customers in Europe and Korea.

The MassArray system, first commercialized in early 2000, provides a platform for genotyping experiments without the use of fluorescence or other tagging techniques. Instead, the company's technology applies MALDI-TOF mass spectrometry directly to fragments of DNA to detect SNPs.  

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.